Yeah--for Peabody--who gets a quarter million for being AK's gopher....
" he will receive a consulting fee of $15,000 per month for services to BioTime and OncoCyte. The Consulting Agreement will terminate on November 18, 2016, or earlier upon: (a) the death or disability of Mr. Peabody;(b) thirty days written notice from Mr. Peabody which may be given after February 28, 2015; (c) written notice from BioTime given at any time after the total payments received by Mr. Peabody from LifeMap Solutions and under the Consulting Agreement total $221,500;
There go all the "REnevia " profits for the next 5 years.
Total thumbs down. BTX abandoned that market, and said so in the 10K of 2011 or so.
But the recent surge of interest in transhumanists who are known Alcor clients no doubt makes this kind of pumping look good again.
Yup...And whatever earnings from the i/p ever arrives will accrue to AK, Neal, and Garfies--while the acccumulated shareholder deficit will go to retail road kill.
And this dog is down ~25% since you started saying that at around 4 3/8.
No stock is ever "worth" more than its realisable future income, although people refusing to learn that means there are plenty of opportunities to trade into accumulation.
The " nice try tho Noah" is false ever since he turned tail and ran when asked about revenues from "Renevia."
(By the way, Biotime has a long history of having employees posting to YHOO, on both public and proivate groups.
At three times what BTX says is the value of its intellectual property, that would be right around 1 3/8 a share.
At 2x, it's under a buck.
That's a net decline per share in the past 3 years.
In the meantime, the T/A is bearish, while the F/A continues at way overpriced.
"Baltbear,I do not know exactly how many....
Do a small DD to know" Hi there game boy. You are the one making the claim. I do recall that Teva made BTX give them some interest in any future that camer froim BTX buying, not "inventing" some tech that TEVA had put a tiny amount of money into.
And yes, of course, gaming the mkts by accessing the corpsicle crowd in Israel did pop this dog for a few weeks. As part of the $100mm in dilution promised in January.
Now, want to get back to answering that "Renevia" question? Or did you want to show any passersby that you're part of the game boy crowd, instead of the share dd crowd?
You are obviously intelligent enough to do the actual work--so?
TEVA owns how many BTX shares? Under what terms? If dit's true, it's in the filngs, so you will havce no trouble posting the data.
noach, Correct? Yeah. At which point you totally change the subject.
But let's do the same high school level exercise on "OpRegen." What's the burn from ititiation to CE Mark?
What's the net ___to BTX___ --not some hposital or doctor, per course of treatment? What's left after COG?
In what decade will it reduce BTX burn rate by 1 cent a share?
What the phrick are you talking about? Talk about "no thought behind it"--you get this week's prize. Newbies here may benefit from learning that you came into BTX at around 4 3/8--how long ago? 3years? 4? Did you learn what I've been sayting--that oif anyone likes this dog, then gtrade into accumulation, and do not fall for any of the "10 by year's end" garbage the pumpers spout?
In the meantime, jmil, can you answer the question? How many doses of roostercomb soup are being served in the EEU per year, for how much money? How fast til BTX can get 40% of that mkt, at what COG? How many years before the "REnevia" revs minus COG pay back the accumulated deficit of getting it to mkt?
At what point does it knock 1 cent a share off the burn rate?
Like: pretend this is a stoick board, not a middle school playground.
Sure. Increasing burn rate, declining earnings as a share of G&A. That trend was guranteed by BTX in January tio be true through at least another $100 million in dilution.
It will be true long after it as well.
Given that you knew the answer---yes, "REnevia" will be just one among any a lot of approved products, the gaminess of the question can lead to your point about "Renevia" being so superior. So why isn't BTX looking to get regulated approval as a new, not generic product?
And, "milestone in the regenerative revolution" means nothing at all to BTX the common stock equity. THat's part of the "long" fallacy that "science =$$$." Science = improvements to quality of life for those that can afford it. Where's BTX's rooster comb soup going to price? Can't be too much above the present mkt. BTX learned that with Hextend. How many units a year? COG? From those, how one could predict what year "Renevia" will be at $1000 above what it cost to get there, and, given the rate of dilution, when it would add 1 cent a share to slowing that dilution. And THAT is what prices the common stock, once retail road kill stops being cannon fodder.
Excellent question. Thumbs up. Quyestion, if there isn't, then why id BTX's attempt at a CE Mark in EEU based on it being a generic equivalent to other versions of rooster comb soup already on the mkt? Did you realise that BTX bought the recipe from the U of Utah, which built on the existing known chemistry as a project for post-grads?
Learn to do the DD. A freebie clue: Bing or Goog "hyaluronic acid matrix." There's dozens of them...... Like Good just gave me back 102,000 results in scholarly citation.
" replies on this board seem to show otherwise." Not: not at all. Replies on this board from people who have played this game as professionals state as a certainty that it makes no difference who gets the shares until they become tradeable under their own ticker, so there is no "squeeze" that AK, Neal and Garfies can force onto the floor. This is 100% games with book-keeping. And 100% a way for BTX to hide burn rate's drive to perpetual dilution.
Until there is an open market in which someone who will pay for those shares at a rate that gets someone else to sell some, it does not matter 1 little bit whether they are "in your account" or not.
But AK and Garfies know that most retail is clueless.
" hasn't exactly performed" By what metric? By p/e, roi, p/b, the stock outperforms the enterprise by anywhere from 6 to 1 to infinity....
The fact that at some point BTX runs out of newbies from retail on which to dump T-stock is the issue.
In 23 years BTX has never once covered G&A from revenues. Everything but C-suite payroll has come from dilution. Dilution made possible by the ignorance of retail as to how bio-tech i/p becomes revenue above COG.
Or that the BOD is beginning to realise what a parasite Mikey is, and looking for something other than dilution as a revenue source.
The CE will be for a "me, too" generic. It's not first in class, by any means. The mkt is already being met; and the actual sales price is thus going to be? For how many units per year? At what COG?